No Impact of Total or Myeloid Cd34+ Cell Numbers on Neutrophil Engraftment and Transplantation-Related Mortality after Allogeneic Pediatric Bone Marrow Transplantation  by Pichler, Herbert et al.
Biol Blood Marrow Transplant 20 (2014) 676e683American Society for Blood
ASBMT
and Marrow TransplantationNo Impact of Total or Myeloid Cd34þ Cell
Numbers on Neutrophil Engraftment and
Transplantation-Related Mortality after
Allogeneic Pediatric Bone Marrow
Transplantation
Herbert Pichler 1, Volker Witt 1, Elisabeth Winter 1,
Heidrun Boztug 1, Evgenia Glogova 2, Ulrike Pötschger 2,
Susanne Matthes-Martin 1, Gerhard Fritsch 2,*
1 Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Department of Pediatrics,
Medical University of Vienna, Austria
2Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, AustriaArticle history:
Received 20 December 2013
Accepted 26 January 2014
Key Words:
Pediatric stem cell
transplantation
Graft composition
Hematopoietic recovery
CD34þ cell doseFinancial disclosure: See Acknowl
* Correspondence and reprint re
Cancer Research Institute, St. Anna
of Pediatrics, Medical University
Vienna, Austria.
E-mail address: gerhard.fritsch@
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Although the inﬂuence of transplanted bone marrow (BM) CD34þ cells on neutrophil engraftment (NE) and
transplantation outcomes has been discussed controversially, thresholds between 2 and 4  106/kg
CD34þ cells are commonly accepted. This has substantial consequences for a donor in terms of BM volume to
be collected, which frequently covers up to 15 to 20 mL/kg. As the BM CD34þ compartment contains varying
fractions of CD34þ/CD19þ B lymphoid progenitors, we tested the hypothesis that the infused CD34þ/
CD45dim/CD19-/CD10- myeloid stem cells might reliably predict NE in 94 children who received BM from 37
HLA-identical sibling donors (MSD) and 57 matched unrelated donors after myeloablative conditioning. The
grafts contained a median of 3.6  106/kg total CD34þ cells, which consisted of a median of 73% myeloid
CD34þ cells and 27% B lymphoid progenitors. Grafts from donors <15 years old yielded signiﬁcantly lower
myeloid fractions compared with grafts from older donors (P < .001). All patients achieved sustained NE after
median 20 (range, 11 to 40) days. By multivariate analysis, neither the number of total CD34þ cells (P ¼ .605)
nor of myeloid CD34þ cells (P ¼ .981) correlated with NE, whereas transplantation from MSD (hazard ratio
[HR] 3.51; P ¼ .019) and the administration of granulocyte colonyestimulating factor (HR 2.24; P ¼ .002)
remained independent factors associated with earlier NE. Furthermore, neither total nor myeloid CD34þ cell
quantities were associated with incidences of severe infections before NE (P ¼ .271 and P ¼ .132) or
transplantation-related mortality (TRM) at day þ100 (P ¼ .294 and P ¼ .490). Taking into account that the
number of transplanted total CD34þ or myeloid CD34þ cells does not seem to have a relevant impact on time
to NE, sepsis rates, or TRM, the need of certain threshold cell numbers should be revisited, at least for pe-
diatric MSD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION the assumption that the myeloid CD34þ subset might better
The assumption that the number of transplanted
CD34þ cells has an impact on engraftment kinetics seems
obvious, and several studies described a correlation between
bone marrow (BM) CD34þ cell content and the kinetics of
neutrophil engraftment (NE) [1-6]. Others, however, did not
ﬁnd such a correlation [7-9]. Discrepant ﬁndings concerning
the relation between CD34þ cell dose and engraftment ki-
netics have also been published in the context of peripheral
stem cell (PBSC) transplantation [2,10-16]. The inconsistency
of these ﬁndings might be explained by heterogeneous pa-
tient and transplantation characteristics and the varying
content of myeloid and lymphoid progenitors within the
CD34þ fraction [17-19].
Akashi et al. reported that common myeloid progenitors
give rise to all myeloid lineages [20-22], which would justifyedgments on page 682.
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Since 2000, our 4-color CD34þ enumeration routine has
included quantiﬁcation of CD34þ/CD19þ B lymphoid pro-
genitor cells and of myeloid subsets (CD34þ/CD45dim/
CD19-/CD10-) [18]. In this retrospective analysis, the number
of infused myeloid stem cells was correlated with NE in 100
consecutive pediatric patients who had received donor BM
after myeloablative conditioning. Next, graft contents, as
well as NE, were correlated with sepsis rates during neu-
tropenia and day þ100 transplantation-related mortality
(TRM) to evaluate any clinical relevance.
PATIENTS AND METHODS
Patients and Transplantation Characteristics
To eliminate confounding factors, such as reduced-intensity condition-
ing, ex vivo T cell depletion, and PBSC or cord blood grafts, 100 consecutive
children and adolescents receiving unmanipulated BM after myeloablative
conditioning between 2000 and 2012 were included in the analysis. Four
patients who had received granulocyte transfusions before engraftment, 1
patient with overt relapse on day þ28, and 1 patient who died on day þ11
were excluded. The median recipient age was 11.7 years (range, 1.0 to
23.1 years). All patients were treated for hemato-oncological diseases, with
acute lymphoblastic or myeloid leukemia accounting for the vast majority.
Fifty-nine patients (63%) received a total body irradiationebased condi-
tioning regimen and 35 (37%) received a busulfan-based chemotherapy,Transplantation.
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HLA-identical/matched sibling donors (MSD) in 37 patients (39%), and 57
(61%) underwent transplantation from matched unrelated donors (MUD).
HLA typing was performed at the allele level for HLA-A, -B, -C, -DRB, and
-DRQ for all donor-recipient pairs, revealing an HLA disparity in 30 unrelated
donors. The median donor age was 32.7 years for MUD and 12.7 years for
MSD (P < .001). Patient and transplantation characteristics are summarized
in Table 1.
Graft-versus-host disease prophylaxis for patients who underwent
transplantation from unrelated donors comprised ATG (Fresenius Biotech,
Graefelﬁng, Germany; 20 mg/kg) or Thymoglobuline (Genzyme Polyclonals
S.A.S., Marcy L’Etoile, France; 2.5 mg/kg) given on 3 consecutive days (days
-3 to -1), serum-level-adjusted cyclosporine A (CyA) commencing on day -1,
and short course methotrexate (MTX) on daysþ1,þ3 andþ6 (56 CyAþMTX;
1 CyA only). Patients who underwent transplantation from MSD primarily
received chemoprophylaxis with CyA. In 5 patients, CyA had to be replaced
by tacrolimus because of adverse effects.
Supportive measures included isolation of patients in laminar airﬂow
units and transfusions of leukocyte-depleted and irradiated red blood cells
or platelets from cytomegalovirus (CMV) -seronegative donors, according to
our local policy. Based on pretransplantation serologic testing for herpes
simplex or varicella zoster virus, seropositive patients received acyclovir
(n ¼ 52) as prophylactic therapy. CMV-positive recipients who underwent
transplantation from CMV-negative donors received prophylactic gancy-
clovir (n¼ 27), and patients with CMV reactivation and detectable CMVDNA
in the peripheral blood between days 7 and þ60 were treated with gan-
cyclovir or cidofovir (n ¼ 4). Recombinant hematopoietic growth factorsTable 1
Patient and Transplant Characteristics
Characteristics Value
Diagnosis
ALL 51 (54%)
AML 17 (18%)
CML 9 (10%)
MDS 4 (4%)
JMML 3 (3%)
NHL 6 (6%)
Secondary AML 4 (4%)
Conditioning regimen
TBI-based 59 (63%)
Chemotherapy-based 35 (37%)
Donor
Matched sibling (MSD) 37 (39%)
Matched unrelated (MUD) 57 (61%)
1-AG-mm 26 (46%)
>1-AG-mm 4 (7%)
GVHD prophylaxis*
CyA 38 (40%)
CyA þ MTX 56 (60%)
Virus prophylaxis
Acyclovir 52 (55%)
Gancyclovir 27 (29%)
Gancyclovir þ cidofovir 4 (4%)
n.a. 11 (12%)
G-CSF before engraftment
Yes 45 (48%)
No 46 (49%)
n.a. 3 (3%)
Age, median (range), yr
Donor age (MSD) 12.7 (2.5-38.6)
Donor age (MUD) 32.7 (20.0-51.0)
Recipient age 11.7 (1.0-23.1)
Cellular graft content, median (range)
Total CD34þ cells 3.6 (.4-17)  106/kg
Myeloid CD34þ cells 2.4 (.4-10)  106/kg
B lymphoid CD34þ cells .9 (.1-7)  106/kg
CD3 þ cells 40 (4.5-133)  106/kg
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia;
CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; JMML,
juvenile myelo-monocytic leukemia; NHL, non-Hodgkin lymphoma; TBI,
total body irradiation; MSD, matched sibling donor; MUD, matched unre-
lated donor; AG-mm, antigene mismatch; GVHD, graft-versus-host disease;
CyA, cyclosporin A; FK506, tacrolimus; MTX, methotrexate; G-CSF, gran-
ulocyte colonyestimulating factor; n.a., not available.
Data presented are n (%) unless otherwise indicated.
* CyA replaced by Tacrolimus in 5 patients.were not routinely used; only patients with severe bacterial or fungal in-
fections before NE were treated with granulocyte-colony stimulating factor
(G-CSF) at 5 mg/kg/day (n ¼ 45).
Graft Characteristics and Stem Cell Quantiﬁcation
The BM from sibling donors was collected at our hospital by aspiration
from posterior iliac crests under general anesthesia. Grafts from unrelated
donors were harvested at the respective collection centers. In case of major
or minor blood group incompatibility, grafts underwent a combined
erythrocyte and plasma depletion by using an apheresis system.
All grafts were analyzed by ﬂow cytometry at our local stem cell labo-
ratory before transplantation. In case of erythrocyte or plasma depletion
because of AB0 incompatibility, the stem cell number was determined after
cell processing. In brief, the content of all CD34þ cells and of myeloid
CD34þ cells (CD34þ/CD45dim/CD19-) were determined by 4-color dual
platform ﬂow cytometry as described previously [23]. Normoblasts were
deﬁned as Syto 16 positive, CD45 negative, and CD71 positive. The WBC
value obtained from the hematology analyzer was adjusted accordingly
before calculation of CD34þ numbers. A FACSCalibur (BD Biosciences, San
Jose, CA) was used for acquisition, and the Paint A Gate software (BD) for
data evaluation. CD34þ cells were deﬁned according to the International
Society of Hematotherapy and Graft Engineering guidelines [24]. They were
deﬁned by their dim CD45 expression and by their position in the lympho-
monocytic window in the forward-scattered light/side-scattered light dot
plot. B lymphoid progenitor cells were determined by coexpression of CD34,
as well as CD19 and by their smaller forward-scattered light properties (left
lymphoid window).
Deﬁnition of Engraftment and Other Endpoints
NEwas deﬁned as the ﬁrst of 3 subsequent days withmore than .5109/
L absolute neutrophil cells in the peripheral blood. Chimerism analyses were
performed on days þ14, þ21, þ28, and þ60, on 6 to 8 FACS-sorted WBC
subpopulations (CD4þ and CD8 þ T cells, CD19þ B cells, NK cells, mono-
cytes, granulocytes, CD34þ cells, and normoblasts) using either ﬂuores-
cence in situ hybridization for patients who underwent transplantation
from sex-mismatched donors, or short tandem repeat PCR, in case of
transplantation from donors of identical gender. According to a determined
median time to NE of 20 days for the whole cohort, the rate of NE at dayþ20
was chosen as primary endpoint.
For sepsis analysis, only severe infections within the neutropenic period
after transplantation were taken into account. Severe bacterial or fungal
infections were considered when patients had symptoms of sepsis, overt
septic shock according to published deﬁnitions [25], positive microbiolog-
ical blood testing, or radiologic ﬁndings suggestive of bacterial or fungal
pneumonia.
Death in continuous complete remission due to transplantation-
associated complications within the ﬁrst 100 days was considered an
event for 100-day TRM.
Overall survival (OS) was deﬁned as the time interval between trans-
plantation and death from any cause. Patients surviving without event were
censored at last follow-up, with a median follow-up time of 3.2 years (range,
.1 to 11.2 years).
Statistical Analysis
To analyze the impact of stem cells dose on engraftment kinetics and
other outcomes (OS, TRM, and sepsis), 3 stem cell groups were deﬁned ac-
cording to the content of total CD34þ cells and of myeloid CD34þ cells:
group I with < 3  106/kg total CD34þ or < 2  106/kg myeloid CD34þcells;
group II with  3 and < 6  106/kg total CD34þ or  2 and < 4  106/kg
myeloid CD34þ cells; and group III with  6  106/kg total CD34þ cells
or 4106/kgmyeloid CD34þ cells. Additional parameters investigated for
their inﬂuence on engraftment and other outcomes included donor type,
donor and recipient age, HLA disparity, conditioning regimen, use of G-CSF,
and prophylactic treatment with antiviral drugs.
The univariate statistical analysis was done in several prospectively
identiﬁed subgroups deﬁned by donor type, HLAmatch, donor and recipient
age, conditioning, and virus prophylaxis. The cumulative incidences of NE,
TRM, and sepsis, and the probability of OS were analyzed according to the
Kaplan-Meier method [26] and compared by the log-rank test. No
competing risks had to be taken into account as all patients achieved NE by
day þ40 and only treatment-related deaths occurred until day þ100. The
cumulative incidence of platelet engraftment (PE) was calculated according
to the method by Kalbﬂeisch and Prentice and compared using Gray’s test
[27]. For other than time-to-event variables, the chi-square test was used to
compare groups for categorical variables and the Wilcoxon rank-sum test
(Kruskal-Wallis test for more than 2 populations) was used for continuous
variables. The impact of the predeﬁned confounding factors on the deﬁned
outcomes was investigated using a multivariate Cox regression with time-
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engraftment” considered its time-dependent character by using a Cox
regression in both univariate and multivariate analysis. The statistical
analysis was done with SAS System V9.2 (2008, SAS Institute, Cary, NC). All P
values <.05 were considered signiﬁcant.
RESULTS
Cellular Graft Composition
The grafts contained a median of 3.6  106/kg total
CD34þ cells (range, .4 to 17  106/kg; data available in all 94
patients), 2.4  106/kg myeloid CD34þ cells (range, .4 to
10  106/kg; data missing in 5 patients), and .9  106/kg B
lymphoid CD34þ cells (range, .1 to 7  106/kg; data missing
in 8 patients). Twenty-nine patients received <2  106/kg
myeloid CD34þ cells. The CD34þ cell population of all grafts
consisted of a median of 73% myeloid CD34þ cells (range,
33% to 100%) and 27% CD34/CD19 coexpressing B lymphoid
progenitors (range, 0 to 67%). The median graft content of
CD3 þ T cells was 40  106/kg (range, 4.5 to 133  106/kg;
data not available in 3 patients). Of note, the median number
of myeloid CD34þ cells and of B lymphoid progenitors and
their distribution differed signiﬁcantly within different
donor age groups. Grafts from donors < 15 years old yielded
signiﬁcantly lower myeloid fractions compared with grafts
from older donor groups (P < .001) (Figure 1). As expected,
donor gender did not correlate with graft composition (P ¼
.420).
Neutrophil Engraftment
All 94 patients achieved sustained NE after a median of
20 days (range, 11 to 40 days). The median time to NE of
patients with early (before dayþ20) and late (after day þ20)
engraftment was 18 and 24 days, respectively. Engraftment
was conﬁrmed by chimerism analysis, which revealed >98%
donor chimerism in the myeloid cell subsets in all patients.
We did not observe any correlation between the total
numbers of all CD34þ cells or of myeloid CD34þ cells infused
and time to NE.
The median time to NE for the total CD34þ cell numbers
was 22 (group I), 19 (group II), and 20 days (group III) (P ¼
.901). Likewise, the median time to NE for the myeloidFigure 1. Proportion of myeloid CD34þ subsets out of total CD34þ cells
within the donor age groups. The donor age groups’ median content of
myeloid CD34þ subsets and their percentage of total CD34þ cells were
2.55  106/kg (61%) for donors <15 years (n ¼ 23), 1.80  106/kg (77%) for
donors  15 and < 27 years (n ¼ 24), 3.90  106/kg (82%) for donors  27 and
< 35 years (n ¼ 22), and 2.50  106/kg (77%) for donors  35 years (n ¼ 25)
(P < .001).CD34þ numbers was 20 (group I), 19 (group II), and 21 days
(group III) (P ¼ .492). The total CD34þ cell content did not
correlate with NE at day þ20: the probabilities of NE at
day þ20 were 44%  8% (group I), 56%  8% (group II), and
59%  12% (group III) (P ¼ .788). Similarly, the number of
myeloid CD34þ cells did not correlate with the probabilities
of NE at dayþ20: 52% 9% (group I), 54% 8% (group II), and
48%  11% (group III) (P ¼ .665) (Figure 2). Of note, the me-
dian time to NE of the 29 patients who received< 2  106/kg
myeloid CD34þ cells was 20 days, and it was18 days for 9
patients receiving <1  106/kg myeloid CD34þ cells.
By univariate analysis, the probability of NE at day þ20
was signiﬁcantly higher in patients who underwent trans-
plantation from MSD compared with those who underwent
transplantation from MUD (73%  7% versus 39%  6%,
P < .001). The median time to NE was 18 days (range, 11 to
30) in patients who underwent transplantation from MSD
and 23 days (range, 14 to 33) in patients who underwent
transplantation from MUD (P < .001) (Table 2).
Earlier NE was observed in patients receiving G-CSF (P ¼
.010) and in patients who underwent transplantation from
younger donors (P ¼ .056). Treatment with gancyclovir had a
negative impact on NE (P ¼ .035) compared with acyclovir,
whereas the conditioning regimen (TBI-based versus
busulfan-based regimen) (P ¼ .362), recipient age (P ¼ .725),Figure 2. Probabilities of neutrophil engraftment at day þ20 for patients of
the respective total CD34þ cell groups (A) and myeloid CD34þ cell groups (B).
Table 2
Neutrophil Engraftment Probabilities and Median Engraftment Time
Variable Number Probability of ANC Engraftment
at Day þ20
P Value* ANC Engraftment,
Median (range), d
P Valuey
Donor type <.001 <.001
MSD 37 .73  .07 18 (11-30)
MUD 57 .39  .06 23 (14-33)
HLA typing results .271 .087
HLA matched 64 .55  .06 19.5 (11-40)
HLA mismatched 30 .47  .09 22.5 (16-36)
Graft stem cell content
Total CD34þ cells .788 .901
<3  106/kg 36 .44  .08 22 (12-40)
3 and < 6  106/kg 41 .56  .08 19 (11-36)
6  106/kg 17 .59  .12 20 (16-25)
Myeloid CD34þ cells .665 .492
<2  106/kg 29 .52  .09 20 (12-36)
2 and < 4  106/kg 39 .54  .08 19 (11-40)
4  106/kg 21 .48  .11 21 (16-25)
n.a. 5 - -
Conditioning .362 .415
TBI-based 59 .47  .07 21 (11-36)
Chemotherapy-based 35 .60  .08 19 (13-40)
Donor age, yr .056 .063
<15 23 .70  .10 18 (11-30)
15 and <27 24 .50  .10 20.5 (12-36)
27 and <35 22 .41  .10 21 (14-33)
35 25 .48  .10 22 (13-40)
Recipient age, yr .725 .196
<7 22 .55  .11 20 (12-36)
7 and <12 29 .52  .09 20 (13-30)
12 and <16 23 .43  .10 23 (11-40)
16 20 .60  .11 19 (12-24)
Virus prophylaxis .035 .022
Acyclovir 52 .60  .07 19 (11-36)
Gancyclovir 31 .39  .09 23 (15-40)
n.a. 11 - -
ANC indicates absolute neutrophil cells; MSD, matched sibling donor; MUD, matched unrelated donor; TBI, total body irradiation; n.a., not available.
* Comparison made with log-rank test.
y Comparison made with Wilcoxon rank-sum test.
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on the probability of NE at day þ20.
When patients who underwent transplantation from
MSD and MUD were analyzed separately, the number of
infused myeloid CD34þ cells did not correlate signiﬁcantly
with the probability of NE at day þ20 (P ¼ .175 and P ¼ .110)
(Figure 3). Furthermore, the number of infused total
CD34þ cells did not correlate with the probability of NE at
day þ20 for patients who underwent transplantation from
MSD (P ¼ .311) but correlated with the probability of NE
at day þ20 for patients who underwent transplantation
from MUD (P ¼ .023). Of note, children who underwent
transplantation from MUD were younger (median recipient
age, 9.9 years versus 14.0 years; P ¼ .005), had older donors
than those who underwent transplantation from MSD
(median donor age, 32.7 versus 12.7 years; P < .001), and
hence, received higher doses of total and of myeloid
CD34þ cells (50% of children who underwent trans-
plantation from MSD received <2  106/kg myeloid
CD34þ cells versus 21% of patients who underwent trans-
plantation from MUD; P ¼ .002).
Bymultivariate analysis, transplantation fromMSD (hazard
ratio [HR], 3.51; 95% conﬁdence interval [CI], 1.23 to 9.96; P ¼
.019) and the administration ofG-CSF (HR, 2.24; CI 1.35 to 3.73;
P¼ .002) remained independent factors associatedwith earlier
NE. In contrast, neither the numbers of total or of myeloid
CD34þ cells, nor donor or recipient age, virus prophylaxis, or
conditioning correlated signiﬁcantly with the time to NE
(Table 3). Because of the limited number of patients, themultivariate analysis was performed for the complete cohort
but not for subgroups, and the results of the multivariate sta-
tistical analysis have to be regarded with caution.
Platelet Engraftment
Out of 91 patients with available PE information, 83 ach-
ieved stable PE (deﬁned as thrombocyte recovery to >20 
109/L peripheral blood for at least 7 days without platelet
transfusions) after a median of 31 (range, 13 to 100) days.
Eight patients died before PE. The median time to PE for the
total CD34þ cell numberswas 33.5 (group I), 34 (group II), and
26 days (group III) (P ¼ .103); the median time to PE for the
myeloid CD34þ numbers was 32 (group I), 36 (group II), and
29 days (group III) (P¼ .451). The total CD34þ cell content did
not signiﬁcantly correlate with PE at day þ31: the probabili-
ties of PE at dayþ31were 45% 9% (group I), 41% 8% (group
II), and 71%  11% (group III) (P ¼ .125). Similarly, the number
ofmyeloid CD34þ cells did not correlatewith the probabilities
of PE at dayþ31: 48% 10% (group I), 39% 8% (group II), and
62%  11% (group III) (P ¼ .498) (Figure 4).
Sepsis during Neutropenia and Day þ100 TRM
Forty-ﬁve patients (48%) experienced severe infections
before engraftment. The number of transplanted total and
myeloid CD34þ cells did not signiﬁcantly correlate with the
incidence of severe infections. Cumulative incidences of
sepsis within the ﬁrst 40 days after transplantation were
38%  9% (group I), 59%  8% (group II), and 38%  11%
(group III) for patients receiving the respective myeloid
Figure 3. Probabilities of neutrophil engraftment at day þ20 for patients of
the respective myeloid CD34þ cell groups after transplantation from sibling
donors (A) and unrelated donors (B).
Table 3
Multivariable Regression Model for Neutrophil Engraftment
Analysis of Maximum Likelihood Estimates
Parameter Parameter Estimate Standard Error Chi- Squ
Total CD34þ cells
<3  106/kg .377 .728 .268
3 and <6  106/kg .273 .552 .245
Myeloid CD34þ cells
<2  106/kg .016 .691 .001
2 and < 4  106/kg .014 .490 .001
Donor
MSD HLA identical 1.254 .532 5.550
MUD HLA identical .096 .346 .077
Donor age, yr
<15 .255 .607 .177
<27 .084 .431 .038
<35 .183 .359 .259
Recipient age, yr
<12 .699 .488 2.055
<16 .830 .468 3.140
<7 .404 .573 .497
Conditioning
Chemotherapy based .400 .333 1.436
Virus prophylaxis
Acyclovir .187 .289 .420
G-CSF
G-CSF given .808 .256 9.942
G-CSF indicates granulocyte colonyestimulating factor; MSD, matched sibling don
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sepsis rates in patients who underwent transplantation from
HLA-mismatched unrelated donors (60%  9%) and MUD
(53%  7%) compared with patients who underwent trans-
plantation from MSD (38%  8%) (P ¼ .178). Other variables
(donor or recipient age, conditioning regimen, virus pro-
phylaxis, or G-CSF) did not signiﬁcantly correlate with the
occurrence of sepsis neither in univariate nor multivariate
analysis (detailed results not shown). Only 1 patient (group
III) experienced invasive aspergillosis.
The cumulative incidence of TRM at day þ100 was
7% 3% for the complete cohort, and it did not correlate with
total CD34þ cell numbers (group I: 3%  3%; group II:
12%  5%; and group III: 6%  6% [P ¼ .294]) or with myeloid
CD34þ cell numbers (group I: 3%  3%; group II: 10%  5%;
and group III: 5%  5% [P ¼ .490]) (Figure 5). None of the
other parameters investigated (donor type, donor or recip-
ient age, conditioning regimen, or virus prophylaxis) had a
signiﬁcant impact on day þ 100 TRM. Because of the limited
number of events, a multivariate analysis was not performed.
Of note, NE within the ﬁrst 20 days after transplantation did
not correlate with day þ100 TRM either: 5 of 49 patients
with early NE and 2 of 45 patients with delayed NE died
because of transplantation-associated reasons.
The estimates of 5-year OS were 81%  7%, 54%  9%, and
79%  11% (P ¼ .053) for patients of the low, middle, and high
total CD34þ group, along with 80%  8%, 58%  9%, and
68% 13% (P¼ .195) for the respectivemyeloid CD34þ groups.
There was no difference in OS for children who underwent
transplantation from either MSD or MUD (5-year OS:
69%  8% versus 69%  7%; P ¼ .863). All other variables
(donor type, donor or recipient age, conditioning, virus pro-
phylaxis) did not signiﬁcantly impact survival in univariate or
multivariate analysis (detailed results not shown).
DISCUSSION
Based on numerous studies in autologous and allogeneic
hematopoietic stem cell transplantation (HSCT), afterare P Value Hazard Ratio 95% Hazard Ratio Conﬁdence Limits
.605 .686 .165-2.856
.621 1.314 .445-3.877
.981 1.017 .262-3.941
.977 1.014 .388-2.647
.019 3.505 1.235-9.952
.782 1.101 .559-2.169
.674 .775 .236-2.544
.845 .919 .395-2.140
.611 1.200 .594-2.428
.152 .497 .191-1.293
.076 .436 .174-1.092
.481 .668 .217-2.053
.231 1.491 .776-2.866
.517 1.206 .685-2.123
.002 2.243 1.358-3.706
or; MUD, matched unrelated donor.
Figure 4. Probabilities of platelet engraftment at day þ31 for patients of the
respective total CD34þ cell groups (A) and myeloid CD34þ cell groups (B). Figure 5. Cumulative incidences of transplantation-related mortality (TRM) at
day þ100 for patients of the respective total CD34þ cell groups (A) and
myeloid CD34þ cell groups (B).
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stem cell content is considered a major determinant of
various transplantation outcomes, including engraftment
kinetics and TRM. There is no doubt that in the context of
unrelated cord blood grafts, the CD34 cell dose plays a sub-
stantial role for both engraftment probability and kinetics, as
well as for TRM [30]. It has been shown in various random-
ized studies that NE is signiﬁcantly faster with PBSC grafts
that contain an up to 5-fold higher number of CD34þ cells as
compared with BM [31-34]. Several studies, however, which
support the impact of the transplanted cell dose on NE, have
included both BM and PBSC grafts [3,14], not taking into
account that the cell source itself might have an inﬂuence on
engraftment kinetics. In the context of PBSC grafts, the cor-
relation between CD34þ cell dose and NE is inconsistent
[10,13,15]. A functional correlation of the BM CD34þ cell
content with NE has been described by some groups [1,4,5],
whereas others reported no association for both related or
unrelated HSCT [7-9]. Consequently, several minimal
threshold CD34þ cell doses between 2 and 4  106/kg have
been proposed [1,2,5].
The heterogeneity of the CD34þ cell compartment
described for different graft sources [17] including BM grafts
[18,19], led us to evaluate the correlation of transplanted
myeloid CD34þ cell subsets with NE in a homogenous group
of pediatric patients who underwent transplantation with
unmanipulated BM from related or unrelated donors after
myeloablative conditioning.The myeloid CD34þ cell fraction was lowest in grafts from
donors < 15 years old and increased with donor age. An age-
dependent increase of myeloid CD34þ subsets, accompanied
by a relative decrease in lymphoid progenitorswas reported in
BM of mice [35-37]. Moreover, an age-dependent decrease in
B lymphoid progenitors in human BM has been proposed
[38,39]. Recently, the persistence ofmyeloid progenitors at the
same level and a declining frequency of lymphoid progenitors
with increasing age were suggested after phenotypic analysis
of 48 BM samples from donors older than 14 years [40].
In our study, the total CD34þ cell number did not corre-
late signiﬁcantly with engraftment kinetics. This is in
contrast to the ﬁndings of Bittencourt et al. in 212 patients
who underwent transplantation with unmanipulated BM
from MSD [1]. However, this study included both adult and
pediatric patients, and donor age was not included as a var-
iable in their multivariate analysis despite a wide range (1.2
to 64.8 years). Marley et al. found an age-dependent relative
increase of myeloid progenitors in human BM, whereas the
capacity to replicate declines with increasing age [41]. It was
furthermore reported that the repopulating capacity of hu-
man BM CD34þ cells from older donors is remarkably
reduced after injection into NOD/SCID/interleukin-2 receptor
gamma-chain-null mice, and that a substantial decrease in
the generation of myeloid cell lines was observed with rising
donor age [40]. Hence, the reported correlation of total
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that younger donors usually have more CD34þ cells/mL BM,
albeit with a high proportion of B cell precursors [42]. Our
ﬁnding that the number of infused total CD34þ cell/kg did
not correlate with NE conﬁrms previous studies [7-9].
The present data refute our original hypothesis that the
number of myeloid stem cells infused might better predict
NE than the number of all CD34þ cells: there was no sig-
niﬁcant correlation of the number of infused myeloid
CD34þ cells with NE in our pediatric patient cohort. These
results are in line with the report by Collins, who did not ﬁnd
a correlation of myeloid or lymphoid subsets of BM grafts
with NE in a cohort including foremost adults who under-
went transplantation from unrelated donors after myeloa-
blative and reduced-intensity conditioning [7]. Notably, NE
in children who underwent transplantation from MUD was
signiﬁcantly delayed as compared with recipients of grafts
from MSD, although they received higher stem cell doses.
This ﬁnding might be explained by a combined effect of
higher donor age, pretransplantation serotherapy, and post-
transplantation methotrexate in patients who underwent
transplantation from MUD.
We are aware that our analysis has some limitations that
should be addressed. At ﬁrst, differences in engraftment ki-
netics might not have gained signiﬁcance because of a
limited number of patients who received low numbers of
total or myeloid CD34þ cells. For example, only 9 patients
received <1  106/kg myeloid CD34þ cells. Therefore, we
cannot rule out that the stem cell doses for patients of group I
were above a certain threshold required for the conﬁrmation
of an evident dose-response relationship. Furthermore,
several studies on hematopoietic recovery after HSCT re-
ported that platelet recovery is strongly inﬂuenced by
transplanted stem cell numbers, in some reports even
stronger than NE [1-4,6,17,43]. Therefore, the transplantation
of lower stem cell numbers might postpone PE. Of note, we
found no signiﬁcant correlation of total and myeloid stem
cell numbers with PE in our pediatric cohort (Figure 4). These
ﬁndings are in line with previous reports [7-9]. However, we
found a nonsigniﬁcant trend towards a faster platelet re-
covery after transplantation of very high (6  106/kg)
numbers of total CD34þ cells but not of myeloid CD34þ cells.
As shown by others, the administration of G-CSF signiﬁ-
cantly enhanced the rate of NE [44,45], although G-CSF was
only administered in case of severe bacterial infections. Of
note, the frequency of G-CSF administration was similar in
patients who underwent transplantation from either siblings
or MUD. The incidence of severe bacterial and fungal in-
fections did not correlate with the number of infused total
and myeloid CD34þ cells.
The general belief that earlier NE is associated with a
decrease in TRM and, thus, improved OS is the rationale for
the paradigm of “the more the better,” and several authors
have correlated the number of CD34þ cells/kg with TRM and
OS [1,2,14]. In the present study, neither TRM at dayþ100 nor
the 5-year OS were signiﬁcantly inﬂuenced by total or
myeloid CD34þ cell doses. Of note, in our study, NE at
day þ20 did not seem to have a signiﬁcant impact on
day þ100 TRM. In a retrospective analysis in adults
comparing PBCSC to BM, Bittencourt et al. did not ﬁnd a
difference in TRM either, despite a signiﬁcantly earlier NE
[46]. Late NE has been described as risk factor for invasive
aspergillosis in adults undergoing HSCT from alternative
donors [47]. Late NE, however, was deﬁned in this study as
NE after day þ40, whereas in our patient cohort, the mediantime to NE of those with late (after day þ20) engraftment
was 24 days, and only 1 patient had NE as late as day þ40.
The belief that a higher number of infused BM stem cells
correlates with earlier NE and, hence, reduces TRM has sig-
niﬁcant consequences for BM donors and, in particular, for
pediatric sibling donors. The common practice of harvesting
at least 1 to 2  108 nucleated cells per kg recipient impli-
cates prolonged general anesthesia, a higher number of BM
biopsies, and an increased need of transfusion. VanWalraven
et al. recently reported that BM volumes exceeding 15 mL/kg
were harvested in 65% of sibling donors under the age of
13 years, and that larger volumes were harvested from do-
nors with older recipients [48]. Of note, in their retrospective
analysis, all patients receiving less than 1  108 nucleated
cells per kg engrafted, and none of them died from
transplantation-related causes. Taking into account the fact
that the cell number infused does not seem to have a relevant
impact on time to engraftment and on TRM in children, and
the increasing ethical concerns about bone marrow donation
of pediatric sibling donors, the need of certain threshold cell
numbers should be revisited.
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